Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
DNA methylation status at diagnosis in MDS predicts response to azacitidine
Qin Yang, Miguel Torres-Martin, Masataka Taguchi, Alice Brogi, Irene Casalin, Eleonora Ceneri, Stephanie Halene, Amy E. DeZern, Elizabeth A. Griffiths, Matilde Y. Follo, Carlo Finelli, Jerald P. Radich, Michael J. Rauh, Rafael Bejar, Mikkael A. Sekeres, Valeria Santini, Maria E. Figueroa
Qin Yang, Miguel Torres-Martin, Masataka Taguchi, Alice Brogi, Irene Casalin, Eleonora Ceneri, Stephanie Halene, Amy E. DeZern, Elizabeth A. Griffiths, Matilde Y. Follo, Carlo Finelli, Jerald P. Radich, Michael J. Rauh, Rafael Bejar, Mikkael A. Sekeres, Valeria Santini, Maria E. Figueroa
View: Text | PDF
Clinical Research and Public Health Genetics Hematology

DNA methylation status at diagnosis in MDS predicts response to azacitidine

  • Text
  • PDF
Abstract

BACKGROUND Myelodysplastic syndromes (MDS) are characterized by aberrant DNA methylation, and mutations in epigenetic modifiers are frequently found in these patients. Although DNA methyltransferase inhibitors are used to treat MDS, response variability remains a challenge in the clinic, with limited predictive markers.METHODS We integrated genomic, epigenomic, and transcriptomic analyses of n = 98 patients with MDS. Patients were classified into epigenetic subtypes via hierarchical clustering. Random forest classifiers were developed and validated using internal stratified testing and an independent external cohort to predict azacitidine (AZA) response.RESULTS MDS are characterized by widespread DNA hypomethylation affecting distal regulatory elements. We identified 7 epigenetic clusters correlated with distinct molecular drivers. Notably, cluster VI exhibited low mutational burden but a high AZA response rate of 71% (P ≤ 0.01). While transcriptional profiles alone failed to distinguish responders, a DNA methylation–based (DNAme-based) classifier achieved an area under the curve (AUC) of 0.82. An integrative model combining DNAme, gene expression, mutations, and clinical parameters achieved an AUC of 0.93 in internal validation and 0.88 in the external cohort.CONCLUSION Epigenetic signatures at distal genomic elements provide superior predictive power for AZA response compared with promoter-centric or transcriptional analyses. These findings establish a robust framework for personalized treatment strategies in MDS.TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01522976.FUNDING NIH National Heart, Lung, and Blood Institute grant: R01HL126947; Leukemia and Lymphoma Society: grants 13-5719, 7028-22.

Authors

Qin Yang, Miguel Torres-Martin, Masataka Taguchi, Alice Brogi, Irene Casalin, Eleonora Ceneri, Stephanie Halene, Amy E. DeZern, Elizabeth A. Griffiths, Matilde Y. Follo, Carlo Finelli, Jerald P. Radich, Michael J. Rauh, Rafael Bejar, Mikkael A. Sekeres, Valeria Santini, Maria E. Figueroa

×

Figure 2

DNAme captures molecular heterogeneity in MDS.

Options: View larger image (or click on image) Download as PowerPoint
DNAme captures molecular heterogeneity in MDS.
(A) Heatmap with hierarch...
(A) Heatmap with hierarchical clustering illustrating the 7 MDS patient clusters identified based on DNAme data, with corresponding mutation and clinical annotations displayed below. Patients harboring gene mutations are color-coded. Cytogenetic risk: VP, very poor; P, poor; INT, intermediate; G, good; VG, very good; NA, not available. WHO 2022: IB1, MDS with increased blasts-1; IB2, MDS with increased blasts-2; LB, MDS with low blasts. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. (B) Heatmap depicting the mutation profiles of each identified cluster. P values were calculated using Fisher’s exact test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. (C) Box plot showing the number of mutations per patient across the identified clusters. The bounds of the boxes represent the 25th and 75th percentiles, the horizontal line within the box indicates the median, and the whiskers extend to the minimum and maximum values. Individual outliers are represented by dots. P values were calculated using the Wilcoxon rank sum test. *, P ≤ 0.05; **, P ≤ 0.01. (D) Bar plot displaying the number of clinical responders and nonresponders within each cluster. P values were calculated using Fisher’s exact test. **, P ≤ 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts